期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 113, 期 2, 页码 208-211出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djaa052
关键词
-
类别
资金
- NCATS NIH HHS [KL2 TR003168] Funding Source: Medline
This study found that residual radiographic tumor following anti-PD1 therapy may not require systematic resection and pathological complete response may be feasible for dMMR mCRC patients. Further larger prospective studies are needed to confirm these findings.
Immune checkpoint inhibition (CPI) for metastatic colorectal cancer (mCRC) with deficient mismatch repair (dMMR) demonstrates high clinical activity that appears durable, but the impact of CPI on pathological tumor response is unknown. In this retrospective analysis, our objective was to assess pathological response and clinical outcomes in dMMR mCRC patients treated with CPI prior to surgical resection of primary and/or metastatic tumor. Among 121 advanced dMMR mCRC patients treated with CPI at 2 institutions between November 2016 and December 2018, 14 underwent surgery. Pathologic complete response was noted in the resected specimens of 13 patients despite the presence of residual tumor on preoperative imaging in 12 of those patients. With median follow-up of 9 months, no patients have had disease relapse or progression. For this small retrospective study, the data suggest that residual radiographic tumor may not require systematic resection following response to anti-PD1-based therapy. However, larger prospective studies are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据